JPWO2015041322A1 - Polyrotaxane in which cyclic molecule has polymer chain and method for producing the same - Google Patents

Abstract

The present invention provides a polyrotaxane having a cyclic molecule having a polymer chain and a method for producing the same, in which the production process is reduced and / or the production time is reduced even when the cyclic molecule is a polyrotaxane having a polymer chain. To do. The present invention relates to a pseudopolyrotaxane in which an opening of a cyclic molecule having active hydrogen selected from the group consisting of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin is included in a skewered manner by linear molecules. Wherein at least a part of the active hydrogen is represented by the following formula I (wherein n is a number from 1 to 7, The polyrotaxane is substituted with a polymer chain represented by the formula (1). [Chemical 1] [Selected figure] None

Description

  The present invention relates to a polyrotaxane in which a cyclic molecule has a polymer chain, a method for producing the same, a crosslinked product having the polyrotaxane, and a method for producing the same.

  Polyrotaxane has properties such as viscoelasticity and low compression set due to the cross-linked products of polyrotaxanes, cross-linked products of polymers other than polyrotaxanes and polyrotaxanes, etc., as the cyclic molecules constituting the polyrotaxane move on linear molecules. Occurs. Since such characteristics can be imparted, the polyrotaxane is expected to have various applications, and its research and development is actively performed.

  For example, Patent Document 1 discloses a polyrotaxane in which part or all of the hydroxyl groups of cyclodextrin, which is a cyclic molecule constituting polyrotaxane, is modified to have a modification group by caprolactone via a hydroxypropyl group. Patent Document 1 provides a modified polyrotaxane soluble in an organic solvent by modifying the hydroxyl group of cyclodextrin with ε-caprolactone or the like.

Patent 4521875.

  However, the modified polyrotaxane having a caprolactone-modified group disclosed in Patent Document 1 has a problem in that there are many steps in the production method, and it takes a lot of time to obtain a modified polyrotaxane as a product. In particular, the process disclosed in Patent Document 1 is not only a process for imparting a modifying group with caprolactone, but also a process for imparting a hydroxypropyl group to the preceding stage, so that a very large number of processes are required to obtain a final product. There is a problem that a process is necessary and a great amount of time is consumed. Moreover, there existed a problem that manufacturing cost increased with the manufacturing process and manufacturing time.

Therefore, an object of the present invention is to solve the above problems.
Specifically, the object of the present invention is to reduce the number of production steps and / or reduce the production time even if the cyclic molecule is a polyrotaxane having a polymer chain. It is providing the polyrotaxane and its manufacturing method.
Moreover, the objective of this invention is providing the crosslinked body which has the polyrotaxane in which a cyclic molecule has a polymer chain in addition to the said objective other than the said objective, and its manufacturing method.

The inventors have found the following invention.
<1> A pseudo-polyrotaxane comprising an opening portion of a cyclic molecule having active hydrogen selected from the group consisting of α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin in a skewered manner by linear molecules A polyrotaxane in which blocking groups are arranged so that cyclic molecules are not eliminated at both ends, and at least a part of the active hydrogen is represented by the following formula I (wherein n is 1 to 7, preferably 2 to 6, more preferably Represents a number of 3 to 5, and m represents an average value of 1 to 12, preferably 3 to 10, more preferably 5 to 9, and the above polyrotaxane is substituted with a polymer chain.

<2> In the above item <1>, the polymer chain represented by the formula I may be a chain obtained by ring-opening polymerization of a cyclic lactone.
<3> In the above item <1> or <2>, the weight average molecular weight of the linear molecule is 3,000 to 500,000, preferably 5,000 to 100,000, more preferably 10,000 to 50,000. It is good to be.

<4> A pseudo-polyrotaxane comprising an opening portion of a cyclic molecule having active hydrogen selected from the group consisting of α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin in a skewered manner by linear molecules A polyrotaxane in which blocking groups are arranged so that cyclic molecules are not eliminated at both ends, and at least a part of the active hydrogen is represented by the above formula I (wherein n and m have the same definitions as above). A method for producing a polyrotaxane substituted with a polymerized chain comprising:
A) a step of preparing a polyrotaxane in which blocking groups are arranged so that the cyclic molecules are not detached at both ends of the pseudopolyrotaxane in which the openings of the cyclic molecules are included in a skewered manner by the linear molecules;
B) a step of mixing a cyclic lactone and a polyrotaxane; and C) a step of adding an organic base to the mixture obtained in the step B) and reacting the cyclic lactone with the polyrotaxane;
To obtain a polyrotaxane in which at least a part of the active hydrogen is substituted with a polymer chain represented by the above formula I.

<5> In the above item <4>, the organic base may be a tertiary amine compound having no active hydrogen in the molecule.
<6> In the above <4> or <5>, the organic base is 1,8-diazabicyclo (5.4.0) undecene-7 (DBU), 1,5-diazabicyclo (4.3.0) nonene-5 (DBN) 1,4-diazabicyclo [2.2.2] octane (DABCO), phosphazene base, 1,5,7-triazabicyclo [4.4.0] dec-5-ene (TBD), 7-methyl-1,5, 1 selected from the group consisting of 7-triazabicyclo [4.4.0] dec-5-ene (MTBD), 1,1,3,3-tetramethylguanidine (TMG), 1-azabicyclo [2.2.2] octane Species, preferably 1,8-diazabicyclo (5.4.0) undecene-7 (DBU), 1,5-diazabicyclo (4.3.0) nonene-5 (DBN), 1,5,7-triazabicyclo [4.4. 0] one selected from the group consisting of deca-5-ene (TBD), 7-methyl-1,5,7-triazabicyclo [4.4.0] dec-5-ene (MTBD), more preferably 1 , 8-Diazabicyclo (5.4.0) undecene- 7 (DBU) or 1,5-diazabicyclo (4.3.0) nonene-5 (DBN).

  <7> In any one of the above items <4> to <6>, the weight average molecular weight of the linear molecule is 3,000 to 500,000, preferably 5,000 to 100,000, more preferably 10,000 to It should be 50,000.

<8> In any one of the above items <2> to <7>, the cyclic lactone is one selected from the group consisting of cyclic lactones having 4 to 10 ring members, preferably a group consisting of cyclic lactones having 4 to 7 ring members. And γ-valerolactone having 6 ring members or ε-caprolactone having 7 ring members is preferable.
<9> In any one of the above items <1> to <8>, the cyclic molecule having active hydrogen may be α-cyclodextrin or γ-cyclodextrin, preferably α-cyclodextrin.

  <10> In any one of the above items <1> to <9>, the linear molecule is polyvinyl alcohol, polyvinylpyrrolidone, poly (meth) acrylic acid, cellulose resin, polyacrylamide, polyethylene oxide, polyethylene glycol, polypropylene glycol. Polyolefin, such as polyvinyl acetal resin, polyvinyl methyl ether, polyamine, polyethyleneimine, casein, gelatin, starch, etc. and / or copolymers thereof, polyethylene, polypropylene, and copolymer resins with other olefin monomers Resin, polyester resin, polyvinyl chloride resin, polystyrene resin, acrylic resin, polycarbonate resin, polyurethane resin, vinyl chloride-vinyl acetate copolymer resin, polyvinyl butyral resin, etc .; And derivatives or modified products thereof, polyisobutylene, polytetrahydrofuran, polyaniline, acrylonitrile-butadiene-styrene copolymer (ABS resin), polyamides such as nylon, polyimides, polydienes such as polyisoprene and polybutadiene, polydimethylsiloxane, etc. Polysiloxanes, polysulfones, polyimines, polyacetic anhydrides, polyureas, polysulfides, polyphosphazenes, polyketones, polyphenylenes, polyhaloolefins, conjugated polymers such as polyacetylene, polythiophene, polylactic acid And a group consisting of these derivatives, preferably polyethylene glycol, polyethylene oxide, polypropylene glycol, polyolefin resin, polydienes And polysiloxanes, more preferably selected from the group consisting of polyethylene glycol, polybutadiene, and polydimethylsiloxane.

  <11> In any one of the above items <1> to <10>, the blocking group is a dinitrophenyl group, cyclodextrin, adamantane group, trityl group, fluorescein, silsesquioxane, pyrene, substituted Benzenes (Substituents include, but are not limited to, alkyl, alkyloxy, hydroxy, halogen, cyano, sulfonyl, carboxyl, amino, phenyl, etc. One or more substituents may be present. ), Optionally substituted polynuclear aromatics (substituents include, but are not limited to, the same as those described above. One or more substituents may be present), and steroids Preferably selected from the group consisting of It is preferably selected from the group consisting of dinitrophenyl groups, cyclodextrins, adamantane groups, trityl groups, fluoresceins, silsesquioxanes, and pyrenes, more preferably adamantane groups or cyclodextrins. It should be similar.

The present invention provides a polyrotaxane having a cyclic molecule having a polymer chain and a method for producing the same, wherein the production steps are reduced and / or the production time is reduced even if the cyclic molecule is a polyrotaxane having a polymer chain. can do.
In addition to the above effects, or in addition to the above effects, the present invention can provide a crosslinked product having a polyrotaxane in which a cyclic molecule has a polymer chain, and a method for producing the same.

Hereinafter, the invention described in the present application will be described in detail.
The present application relates to a pseudopolyrotaxane in which openings of a cyclic molecule having active hydrogen selected from the group consisting of α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin are included in a skewered manner by linear molecules. A polyrotaxane in which blocking groups are arranged so that cyclic molecules are not eliminated at both ends, and at least a part of the active hydrogen is represented by the following formula I (wherein n is 1 to 7, preferably 2 to 6, more preferably Represents a number of 3 to 5, and m represents an average value of 1 to 12, preferably 3 to 10, more preferably 5 to 9, and a polyrotaxane substituted with a polymer chain. Moreover, this application discloses the manufacturing method of this polyrotaxane. Hereinafter, the polyrotaxane of this application and its manufacturing method are demonstrated.

<Polyrotaxane whose cyclic molecule has a polymer chain>
The cyclic molecule of the polyrotaxane of the present application has active hydrogen, and has a structure in which at least a part of the active hydrogen is substituted with a polymer chain represented by the above formula I.
The cyclic molecule is selected from the group consisting of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, preferably α-cyclodextrin or γ-cyclodextrin, more preferably α-cyclodextrin. It is good to be.

The “active hydrogen” refers to “H” of 18 OH groups present in the α-cyclodextrin molecule, taking α-cyclodextrin as an example. In the case of β-cyclodextrin and γ-cyclodextrin, the term “H” of OH groups present in these molecules is also used.
The polyrotaxane has one or more cyclic molecules in one molecule of the polyrotaxane, and at least a part of the active hydrogen of the one or more cyclic molecules is substituted with the polymer chain represented by the above formula I. In addition, the polyrotaxane of the present application has a structure in which “H” of at least one OH group among 18 OH groups contained in one molecule of a cyclic molecule is substituted with a polymer chain represented by the above formula I. do it.

When the polyrotaxane of the present application is briefly compared with the polyrotaxane described in Patent No. 4521875 described above as Patent Document 1, the polyrotaxane described in Patent Document 1 is a part or all of the hydroxyl groups of cyclodextrin which is a cyclic molecule. Is a hydroxypropyl group, and the hydroxypropyl group is further modified with caprolactone, whereas the polyrotaxane of the present application is different in that the cyclic molecule directly has a polymer chain without the hydroxypropyl group being interposed.
Because of this difference, the polyrotaxane of the present application can be obtained without providing a step of substituting part or all of the hydroxyl groups of the cyclodextrin, which is a cyclic molecule, with a hydroxypropyl group. Have.

<< polymer chain >>
In the polymer chain represented by the above formula I, n is 1 to 7, preferably 2 to 6, more preferably 3 to 5, and m is 1 to 12, preferably 3 to 10, as an average value. Preferably the number of 5-9 is good.
The value of n or m can be identified by ¹ H-NMR.

The polymer chain represented by Formula I may be a chain obtained by ring-opening polymerization of a cyclic lactone.
The cyclic lactone is one selected from the group consisting of cyclic lactones having 4 to 10 ring members, preferably one selected from the group consisting of cyclic lactones having 4 to 7 ring members, more preferably γ having 6 ring members. -Valerolactone or ε-caprolactone having 7 ring members is preferred.

The polyrotaxane cyclic molecule of the present application has the above polymer chain, but may have other groups.
Other groups include acetyl group, propionyl group, hexanoyl group, methyl group, ethyl group, propyl group, 2-hydroxypropyl group, 1,2-dihydroxypropyl group, cyclohexyl group, butylcarbamoyl group, hexylcarbamoyl group, phenyl group , A polycaprolactone group, an alkoxysilane group, an acryloyl group, a methacryloyl group, a cinnamoyl group, or a derivative thereof, but is not limited thereto.

<< Linear molecule >>
The linear molecule of the polyrotaxane of the present invention is not particularly limited as long as it can be included in a skewered manner in the opening of the cyclic molecule to be used.
For example, as linear molecules, polyvinyl alcohol, polyvinyl pyrrolidone, poly (meth) acrylic acid, cellulosic resins (carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, etc.), polyacrylamide, polyethylene oxide, polyethylene glycol, polypropylene glycol, polyvinyl Polyolefin resins such as acetal resins, polyvinyl methyl ether, polyamines, polyethyleneimine, casein, gelatin, starch, and / or copolymers thereof, polyethylene, polypropylene, and copolymers of other olefin monomers; Polyester resins, polyvinyl chloride resins, polystyrene resins such as polystyrene and acrylonitrile-styrene copolymer resins, polymethyl Acrylic resins such as tacrylate, (meth) acrylic acid ester copolymer, acrylonitrile-methyl acrylate copolymer resin, polycarbonate resin, polyurethane resin, vinyl chloride-vinyl acetate copolymer resin, polyvinyl butyral resin, etc .; and their derivatives or Modified products, polyisobutylene, polytetrahydrofuran, polyaniline, acrylonitrile-butadiene-styrene copolymer (ABS resin), polyamides such as nylon, polyimides, polydienes such as polyisoprene and polybutadiene, polysiloxanes such as polydimethylsiloxane , Polysulfones, polyimines, polyacetic anhydrides, polyureas, polysulfides, polyphosphazenes, polyketones, polyphenylenes, polyhaloolefins, and It may be selected from the group consisting of these derivatives. For example, it may be selected from the group consisting of polyethylene glycol, polyisoprene, polyisobutylene, polybutadiene, polypropylene glycol, polytetrahydrofuran, polydimethylsiloxane, polyethylene, polypropylene, polyvinyl alcohol and polyvinyl methyl ether. Particularly preferred is polyethylene glycol.

The linear molecule should have a weight average molecular weight of 3,000 to 500,000, preferably 5,000 to 100,000, more preferably 10,000 to 50,000.
In addition, the weight average molecular weight of a linear molecule | numerator can be measured by a gel permeation chromatography (Gel Permeation Chromatography, GPC). GPC measurement conditions depend on the type of linear molecule, but the type of eluent, column, temperature, and standard substance should be appropriately selected.
In the polyrotaxane of the present application, the combination of (cyclic molecule, linear molecule) may be (derived from α-cyclodextrin, derived from polyethylene glycol).

<< Blocking group >>
The blocking group of the polyrotaxane of the present application is not particularly limited as long as it is a group that is arranged at both ends of the pseudopolyrotaxane and acts so that the cyclic molecule to be used does not leave.
For example, as a blocking group, dinitrophenyl groups, cyclodextrins, adamantane groups, trityl groups, fluoresceins, silsesquioxanes, pyrenes, substituted benzenes (substituents are alkyl, alkyloxy, hydroxy, Examples include, but are not limited to, halogen, cyano, sulfonyl, carboxyl, amino, phenyl, etc. One or more substituents may be present), optionally substituted polynuclear aromatics (substituted) Examples of the group include, but are not limited to, the same as described above, and one or more substituents may be present.) And a group consisting of steroids. It is preferably selected from the group consisting of dinitrophenyl groups, cyclodextrins, adamantane groups, trityl groups, fluoresceins, silsesquioxanes, and pyrenes, more preferably adamantane groups or cyclodextrins. It should be similar.

<Method for producing polyrotaxane of the present application>
This application provides the manufacturing method of the above-mentioned polyrotaxane.
The polyrotaxane of the present application is, for example,
A) Both ends of a pseudopolyrotaxane in which openings of a cyclic molecule having active hydrogen selected from the group consisting of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin are included in a skewered manner by linear molecules And a step of preparing a polyrotaxane having a blocking group arranged so that the cyclic molecule is not eliminated;
B) a step of mixing a cyclic lactone and a polyrotaxane; and C) a step of adding an organic base to the mixture obtained in the step B) and reacting the cyclic lactone with the polyrotaxane;
Can be obtained.
Hereinafter, each step will be described. The term “active hydrogen” has the same definition as described above. In addition, the cyclic molecule, the linear molecule, the blocking group, and the cyclic lactone are as described above.

  Step A) is a step of preparing a polyrotaxane. This step can be obtained by WO2005 / 052026 (the entirety of which is included in the present specification as a reference).

Step B) is a step of mixing the polyrotaxane obtained in step A) and the cyclic lactone.
Mixing can be performed by a conventionally known method.
Although the cyclic lactone can also act as a solvent, "other solvents" may be used in addition to the cyclic lactone as the solvent. However, when “other solvents” are used, it is preferable to use those which do not adversely affect the reaction in the step C) described later. For example, as "other solvents", dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMAc), xylene, toluene, tetrahydrofuran (THF), methyl acetate, ethyl acetate, butyl acetate, dichloromethane, chloroform, acrylonitrile However, it is not limited to these.

In step C), an organic base is added to the mixture obtained in step B), and the cyclic lactone and polyrotaxane are reacted.
The organic base is not particularly limited as long as it reacts a cyclic lactone with a polyrotaxane, and particularly reacts a cyclic lactone with an active hydrogen in the cyclic molecule of the polyrotaxane, but a tertiary amine having no active hydrogen in the molecule. Preferably it is a compound.

  In particular, organic bases are 1,8-diazabicyclo (5.4.0) undecene-7 (DBU), 1,5-diazabicyclo (4.3.0) nonene-5 (DBN), 1,4-diazabicyclo [2.2.2]. Octane (DABCO), phosphazene base, 1,5,7-triazabicyclo [4.4.0] dec-5-ene (TBD), 7-methyl-1,5,7-triazabicyclo [4.4.0] deca One selected from the group consisting of -5-ene (MTBD), 1,1,3,3-tetramethylguanidine (TMG) and 1-azabicyclo [2.2.2] octane, preferably 1,8-diazabicyclo (5.4 .0) Undecene-7 (DBU), 1,5-diazabicyclo (4.3.0) nonene-5 (DBN), 1,5,7-triazabicyclo [4.4.0] dec-5-ene (TBD), One selected from the group consisting of 7-methyl-1,5,7-triazabicyclo [4.4.0] dec-5-ene (MTBD), more preferably 1,8-diazabicyclo (5.4.0) undecene- 7 (DBU) or 1,5-diazabisk (4.3.0) nonene-5 is a good is a (DBN).

  The reaction conditions of step C) depend on the cyclic lactone used, the polyrotaxane used, the organic base used, etc., but pressure: normal pressure, temperature: 30-150 ° C. under dehydration conditions such as nitrogen atmosphere, time: 0.5- For example, 24 hours.

Although the polyrotaxane of this application can be obtained by the said A) -C) process, you may have processes other than said A) -C) process.
For example, a step of drying the polyrotaxane and / or cyclic lactone and / or a mixture thereof is provided before step C), specifically after step A), before step B) and / or after step B). Good. In the step C), if there is unnecessary active hydrogen, specifically, active hydrogen derived from moisture, the above-mentioned drying step is preferably provided in order to inhibit a desired reaction.

  It is preferable to provide a step of purifying the obtained polyrotaxane after the step C). In particular, it is preferable to provide a treatment step for reducing the activity of the organic base used in step C) or a treatment step for removing the organic base. For example, as a treatment step for reducing the activity of the organic base, a step for neutralizing the organic base with an organic acid such as acetic acid; a treatment step for removing the organic base; a precipitation purification step using a poor solvent; Examples thereof include, but are not limited to, a removal step, an organic base adsorption / removal step using an adsorbent, and the like.

  The polyrotaxane of the present application may be used as a starting material. For example, the present application can provide a crosslinked product obtained by crosslinking the polyrotaxane of the present application with the polyrotaxane of the present application as a starting material. Moreover, the crosslinked body which bridge | crosslinked polyrotaxane of this application and polyrotaxanes other than the polyrotaxane of this application can also be provided. Furthermore, the crosslinked body which bridge | crosslinked the polyrotaxane of this application and polymers other than a polyrotaxane can also be provided. In addition, these bridge | crosslinking bodies can be prepared by the method described in WO2001 / 083566, WO2005 / 052026, WO2005 / 095493, etc., for example.

  EXAMPLES Hereinafter, although this invention is demonstrated further in detail based on an Example, this invention is not limited to a present Example.

<Preparation of Synthesis Example 1 APR35K>
<< Preparation of PEG-carboxylic acid by TEMPO oxidation of PEG >>
10 g of PEG (molecular weight 35,000), 100 mg of TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy radical), and 1 g of sodium bromide were dissolved in 100 ml of water. 5 ml of a commercially available sodium hypochlorite aqueous solution (effective chlorine concentration of about 5%) was added to the resulting solution, and the mixture was reacted at room temperature with stirring. As the reaction progressed, the pH of the system rapidly decreased immediately after the addition, but was prepared by adding 1N NaOH so as to keep the pH: 10-11 as much as possible. The decrease in pH disappeared within about 3 minutes, but the mixture was further stirred for 10 minutes. Ethanol was added in a range up to 5 ml to terminate the reaction. Extraction with 50 ml of methylene chloride was repeated three times to extract components other than inorganic salts, and then methylene chloride was distilled off with an evaporator. After dissolving in 250 ml of warm ethanol, PEG-carboxylic acid, that is, one in which both ends of PEG were replaced with carboxylic acid (—COOH) was deposited overnight in a −4 ° C. freezer. The precipitated PEG-carboxylic acid was collected by centrifugation. This cycle of warm ethanol dissolution-precipitation-centrifugation was repeated several times, and finally dried by vacuum drying to obtain PEG-carboxylic acid. Yield 95% or more. Carboxylation rate is 95% or more.

<< Preparation of inclusion complex using PEG-carboxylic acid and α-CD >>
After dissolving 3 g of PEG-carboxylic acid prepared above and 9 g of α-CD in 50 ml of warm water of 70 ° C. separately prepared, both were mixed, and then allowed to stand overnight in a refrigerator (4 ° C.). The inclusion complex precipitated in the form of cream was lyophilized and recovered.

<< Cleavage of inclusion complex using adamantaneamine and BOP reagent reaction system >>
To the above inclusion complex, 0.13 g of adamantaneamine, 0.38 g of BOP reagent (benzotriazol-1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophosphate) and 0.14 ml of diisopropylethylamine were added with dehydrated dimethylformamide (DMF). ) A solution dissolved in 50 ml was added, shaken well, and then allowed to stand overnight in a refrigerator. Thereafter, 50 ml of methanol was added, and stirring, centrifugation, and removal of the supernatant were performed. Subsequently, 100 ml of DMF / methanol = 1: 1 mixed solution was added, and the same operation was performed twice. Further, the same operation was performed twice using 100 ml of methanol, and the resulting precipitate was vacuum-dried and then dissolved in 50 ml of dimethyl sulfoxide (DMSO). This solution was dropped into 700 ml of pure water to precipitate polyrotaxane. The precipitated polyrotaxane was collected by centrifugation and vacuum dried. Further, the same reprecipitation operation was performed to obtain a polyrotaxane (main chain molecular weight: 35,000) (hereinafter abbreviated as “APR35K”).
When the weight average molecular weight of the obtained APR35K was measured by GPC, it was found to be 100,000. GPC measurement conditions were as follows: TOSOH HLC-8220 GPC apparatus, column: TSK guard column Super AW-H and TSKgel Super AWM-H (two linked), eluent: dimethyl sulfoxide / 0.01M LiBr, column Oven: 50 ° C., flow rate: 0.5 ml / min, sample concentration: about 0.2 wt / vol%, injection amount: 20 μl, pretreatment: filtration through a 0.2 μm filter, standard molecular weight: PEO (polyethylene oxide) there were.

<Synthesis Example 2 Preparation of APR20K>
APR20K was obtained in the same manner as in <Synthesis Example 1> except that PEG (molecular weight 20,000) was used instead of PEG (molecular weight 35,000) in <Synthesis Example 1>. When the weight average molecular weight of the obtained APR20K was measured by GPC in the same manner as in <Synthesis Example 1>, it was found to be 60,000.

<Synthesis Example 3 Preparation of APR10K>
APR10K was obtained in the same manner as in <Synthesis Example 1> except that PEG (molecular weight 10,000) was used instead of PEG (molecular weight 35,000) in <Synthesis Example 1>. When the weight average molecular weight of the obtained APR10K was measured by GPC in the same manner as in <Synthesis Example 1>, it was found to be 37,000.

<Grafting to APR35K>
APR35K (1 g) and ε-caprolactone (10 g) were placed in a two-necked eggplant flask and dried for 2 hours under a nitrogen stream condition while heating and stirring at 110 ° C. in an oil bath. After drying, DBU (1 ml) was added, and the reaction was carried out for 30 minutes under a nitrogen stream while stirring and heating to 130 ° C. in an oil bath. After the reaction, the reaction mixture was neutralized by adding acetic acid (1 ml) and purified by precipitation with methanol. The obtained precipitate was dried under reduced pressure to obtain a graft body (7.75 g) in which polycaprolactone was grafted to α-cyclodextrin, which is a cyclic molecule of APR35K.
In addition, it confirmed by < ¹ > H-NMR that the average degree of polymerization of the obtained polycaprolactone chain | strand, ie, the average value of m of the polymer chain represented by Formula I, was 7. n was 5 from the ε-caprolactone used.

<Grafting to APR35K>
A graft obtained by grafting polycaprolactone to α-cyclodextrin, which is a cyclic molecule of APR35K, in the same manner as in Example 1, except that DBN (1 ml) was used instead of DBU (1 ml) used in Example 1. A body (7.45 g) was obtained.
In addition, it confirmed by < ¹ > H-NMR that the average degree of polymerization of the obtained polycaprolactone chain | strand, ie, the average value of m of the polymer chain represented by Formula I, was 9. Note that n was 5.

<Grafting to APR35K>
Polycaprolactone was grafted onto α-cyclodextrin, which is a cyclic molecule of APR35K, in the same manner as in Example 1, except that ε-caprolactone (6 g) was used instead of ε-caprolactone (10 g) used in Example 1. A grafted product (5 g) was obtained.
In addition, it confirmed by < ¹ > H-NMR that the average degree of polymerization of the obtained polycaprolactone chain | strand, ie, the average value of m of the polymer chain represented by Formula I, was 5.5. Note that n was 5.

<Grafting to APR35K>
Except that the amount of DBU used in Example 3 was 0.2 ml instead of 1 ml, the reaction time was 5 hours instead of 30 minutes, and the amount of acetic acid after the reaction was 0.2 ml instead of 1 ml. In the same manner as in Example 1, a graft product (5.4 g) in which polycaprolactone was grafted to α-cyclodextrin, which is a cyclic molecule of APR35K, was obtained.
In addition, it confirmed by < ¹ > H-NMR that the average degree of polymerization of the obtained polycaprolactone chain | strand, ie, the average value of m of the polymer chain represented by Formula I, was 8. Note that n was 5.

<Grafting to APR35K>
The amount of ε-caprolactone used in Example 1 was 4.5 g instead of 10 g, the amount of DBU was 0.4 ml instead of 1 ml, the reaction time was 2 hours instead of 30 minutes, and the acetic acid after the reaction A graft body (4.15 g) obtained by grafting polycaprolactone to α-cyclodextrin, which is a cyclic molecule of APR35K, was obtained in the same manner as in Example 1 except that the amount was 0.4 ml instead of 1 ml. .
In addition, it confirmed by < ¹ > H-NMR that the average degree of polymerization of the obtained polycaprolactone chain | strand, ie, the average value of m of the polymer chain represented by Formula I, was 6.5. Note that n was 5.

<Grafting to APR20K>
APR20K (1 g) and ε-caprolactone (6 g) were placed in a two-necked eggplant flask and dried for 2 hours under a nitrogen stream condition while heating and stirring at 110 ° C. in an oil bath. After drying, DBU (0.4 ml) was added and the reaction was carried out for 2 hours under a nitrogen stream condition while heating and stirring at 130 ° C. in an oil bath. After the reaction, the reaction mixture was neutralized by adding acetic acid (0.4 ml) and purified by precipitation with methanol. The obtained precipitate was dried under reduced pressure to obtain a graft product (5.15 g) in which polycaprolactone was grafted to α-cyclodextrin, which is a cyclic molecule of APR20K.
In addition, it confirmed by < ¹ > H-NMR that the average degree of polymerization of the obtained polycaprolactone chain | strand, ie, the average value of m of the polymer chain represented by Formula I, was 5.6. Note that n was 5.

<Grafting to APR10K>
APR10K (1 g) and ε-caprolactone (6 g) were placed in a two-necked eggplant flask and dried for 2 hours under a nitrogen stream condition while heating and stirring at 110 ° C. in an oil bath. After drying, DBU (0.4 ml) was added and the reaction was carried out for 2 hours under a nitrogen stream condition while heating and stirring at 130 ° C. in an oil bath. After the reaction, the reaction mixture was neutralized by adding acetic acid (0.4 ml) and purified by precipitation with methanol. The obtained precipitate was dried under reduced pressure to obtain a graft product (5.04 g) in which polycaprolactone was grafted to α-cyclodextrin, which is a cyclic molecule of APR10K.
In addition, it confirmed by < ¹ > H-NMR that the average degree of polymerization of the obtained polycaprolactone chain | strand, ie, the average value of m of the polymer chain represented by Formula I, was 8. Note that n was 5.

Claims (7)

Cyclic polyrotaxanes in which openings of cyclic molecules having active hydrogen selected from the group consisting of α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin are included in a skewered manner by linear molecules are cyclic at both ends. A polyrotaxane in which a blocking group is arranged so that molecules do not leave, wherein at least a part of the active hydrogen is represented by the following formula I (wherein n represents a number of 1 to 7 and m is an average value of 1 The polyrotaxane is substituted with a polymer chain represented by the formula:

  The polyrotaxane according to claim 1, wherein the polymer chain represented by the formula I is a chain obtained by ring-opening polymerization of a cyclic lactone.   The polyrotaxane according to claim 1 or 2, wherein the linear molecule has a weight average molecular weight of 3,000 to 500,000. Cyclic polyrotaxanes in which openings of cyclic molecules having active hydrogen selected from the group consisting of α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin are included in a skewered manner by linear molecules are cyclic at both ends. A polyrotaxane in which a blocking group is arranged so that molecules do not leave, wherein at least a part of the active hydrogen is represented by the following formula I (wherein n represents a number of 1 to 7 and m is an average value of 1 A method for producing a polyrotaxane substituted with a polymer chain represented by:
A) a step of preparing a polyrotaxane in which blocking groups are arranged so that the cyclic molecules are not detached at both ends of a pseudopolyrotaxane in which the openings of the cyclic molecules are included in a skewered manner by linear molecules;
B) a step of mixing the cyclic lactone and the polyrotaxane; and C) a step of adding an organic base to the mixture obtained in the step B) and reacting the cyclic lactone with the polyrotaxane;
To obtain a polyrotaxane in which at least a part of the active hydrogen is substituted with a polymer chain represented by the formula I.

  The method according to claim 4, wherein the organic base is a tertiary amine compound having no active hydrogen in the molecule.   The organic base is 1,8-diazabicyclo (5.4.0) undecene-7 (DBU), 1,5-diazabicyclo (4.3.0) nonene-5 (DBN), 1,4-diazabicyclo [2.2.2] octane. (DABCO), phosphazene base, 1,5,7-triazabicyclo [4.4.0] deca-5-ene (TBD), 7-methyl-1,5,7-triazabicyclo [4.4.0] deca- The method according to claim 4 or 5, which is one selected from the group consisting of 5-ene (MTBD), 1,1,3,3-tetramethylguanidine (TMG), and 1-azabicyclo [2.2.2] octane.   The polyrotaxane according to any one of claims 4 to 6, wherein the linear molecule has a weight average molecular weight of 3,000 to 500,000.